StockDriftsStockDriftsBodytech Med (206640) has 3 disclosed insider purchases and 3 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩609M ($423K) in reported transaction value. The earliest filing StockDrifts holds for Bodytech Med is dated 2024-01-01; the most recent is 2026-04-06. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +7.99%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | BUY | Market Buy | 장덕환 Deok-Hwan Jang | Managing Director | 4.0K | ₩10,520 | +13.3% | ₩42M ($29K) |
| 2026-04-06 | BUY | 수증 | 최규리 Gyuri Choi | moving | 1.2M | ₩10,520 | +13.3% | ₩12.6B ($8.8M) |
| 2026-04-06 | SELL | 증여 | 최의열 Choi Eui-yeol | CEO | -2.4M | ₩10,520 | -13.3% | ₩25.2B ($17.5M) |
| 2026-01-28 | BUY | Market Buy | 장덕환 Deok-Hwan Jang | Managing Director | 3.0K | ₩13,110 | +3.7% | ₩39M ($27K) |
| 2026-01-27 | BUY | Market Buy | 장덕환 Deok-Hwan Jang | Managing Director | 3.0K | ₩12,850 | +5.8% | ₩39M ($27K) |
| 2025-08-13 | SELL | Market Sell | 남기봉 Nam Gi-bong | moving | -18.0K | ₩14,240 | +4.5% | ₩256M ($178K) |
| 2025-06-19 | SELL | Market Sell | 남기봉 Nam Gi-bong | moving | -2.0K | ₩15,100 | +9.9% | ₩30M ($21K) |
| 2025-06-18 | SELL | Market Sell | 남기봉 Nam Gi-bong | moving | -13.3K | ₩15,220 | +10.6% | ₩203M ($141K) |
| 2025-03-26 | SELL | 증여 | 남기봉 Nam Gi-bong | moving | -80.0K | ₩15,620 | +12.9% | ₩1.2B ($868K) |
| 2024-01-09 | BUY | 기타 | 박대균 Park Dae-gyun | moving | 1.1K | ₩19,400 | -29.9% | ₩21M ($15K) |
| 2024-01-01 | BUY | 신규선임 | 김진수 Jinsu Kim | moving | 1.6K | ₩20,300 | -33.0% | ₩32M ($22K) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Bodytech Med. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.